What is the 13F Pro Quality Score for TENX?

13F Pro ranks TENAX THERAPEUTICS, INC. (TENX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TENX's current score at https://13fpro.ai/research/TENX (free sign-up required for the full ranking).

Which hedge funds own the most TENX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TENX include JANUS HENDERSON GROUP PLC, VR Adviser,, PERCEPTIVE ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TENX as soon as new 13F filings post.

Where does 13F Pro source TENX data?

All TENAX THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. TENAX THERAPEUTICS, INC. files with the SEC under CIK 34956. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TENX in?

TENAX THERAPEUTICS, INC. (TENX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TENX research updated on 13F Pro?

TENX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TENAX THERAPEUTICS, INC.(TENX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 34956 TENX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.9M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TENX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TENAX THERAPEUTICS, INC. (TENX), a Healthcare sector company. TENX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.9m in revenue. Based on the latest XBRL financial filings (Q1 2026), TENAX THERAPEUTICS, INC. reports net income of $-15.7M, free cash flow of $-9.3M. Top institutional holders of TENX by reported 13-F value include JANUS HENDERSON GROUP PLC, VR Adviser,, PERCEPTIVE ADVISORS, based on the most recent SEC filings. TENX trades on the Nasdaq exchange and files with the SEC under CIK 34956. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TENX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TENAX THERAPEUTICS, INC. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-15.7M

Free Cash Flow

Q1 2026

$-9.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2024

FY18 —FY21 —FY23 —FY24 $0.00

Net Income

-128.2% YoY

$-17.6MFY 2024

FY18 $-14.1MFY21 $-32.5MFY23 $-7.7MFY24 $-17.6M

Operating Income

-136.8% YoY

$-19.5MFY 2024

FY18 $-6.9MFY21 $-32.7MFY23 $-8.2MFY24 $-19.5M

EPS (Diluted)

+96.3% YoY

$-1.15FY 2024

FY18 —FY21 —FY23 $-31.04FY24 $-1.15

Total Assets

+727.5% YoY

$96.7MFY 2024

FY18 $13.3MFY21 $6.0MFY23 $11.7MFY24 $96.7M

Op. Cash Flow

-150.9% YoY

$-14.8MFY 2024

FY18 $-5.5MFY21 $-10.9MFY23 $-5.9MFY24 $-14.8M

Metric	FY 2024	FY 2023	FY 2021	FY 2018	FY 2016	FY 2015
Revenue	$0.00	—	—	—	$0.00	—
Net Income	$-17.6M -128.2%	$-7.7M +76.3%	$-32.5M -129.6%	$-14.1M +67.8%	$-43.9M	—
Operating Income	$-19.5M -136.8%	$-8.2M +74.8%	$-32.7M -374.8%	$-6.9M +86.9%	$-52.7M	—
EPS (Diluted)	$-1.15 +96.3%	$-31.04	—	—	—	—
Total Assets	$96.7M +727.5%	$11.7M +95.0%	$6.0M -55.1%	$13.3M -42.9%	$23.3M -68.0%	$73.0M
Operating Cash Flow	$-14.8M -150.9%	$-5.9M +45.6%	$-10.9M -97.4%	$-5.5M +65.3%	$-15.9M	—

AI Insight: TENX Financial Trends

Pre-revenue biotech burning $16M quarterly with no revenue inflection; equity base stable but cash runway increasingly constrained.

• Operating cash burn accelerated to $9–13M per quarter in 2025–2026 from $3–7M in late 2024.

• Net losses remain severe at $10–16M per quarter across all 2025 and Q1 2026, with no revenue generation.

• Equity base fluctuated between $92M and $115M; Q1 2026 equity rebounded to $115M despite ongoing losses.

⚠ Quarterly cash burn now $9–13M; at current rate, equity buffer exhausted within 9–12 quarters without new funding.

⚠ No revenue milestone achieved; clinical-stage risk remains unresolved. Equity volatility suggests dilutive capital raises.

AI Insight: TENX Ratio Trends

TENX remains deeply unprofitable with negative returns across all metrics; Q3 2025 marked the nadir, with modest stabilization evident in Q4 2025–Q1 2026.

• ROE deteriorated from -16.3% in Q3 2024 to -65.7% in Q3 2025, then partially recovered to -54.8% in Q1 2026.

• ROIC plummeted from -81.4% in Q3 2024 through -69.9% in Q3 2025, improving to -57.8% in Q1 2026.

⚠ Q3 2025 saw peak losses (ROE -65.7%, ROA -61.5%); sequential stabilization in Q4–Q1 needs confirmation it signals inflection, not noise.

⚠ No margin or leverage data available; cash burn trajectory and path to profitability remain opaque.

Get alerted when TENX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TENAX THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TENX

JANUS HENDERSON GROUP PLC
$29.1M1,815,474 sh
VR Adviser, LLC
$26.8M1,675,262 sh
PERCEPTIVE ADVISORS LLC
$23.2M1,447,782 sh
Ikarian Capital, LLC
$16.3M1,017,600 sh
Stonepine Capital Management, LLC
$15.6M975,200 sh
Logos Global Management LP
$10.0M625,000 sh
MORGAN STANLEY
$9.5M596,564 sh
Velan Capital Investment Management LP
$9.3M583,333 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$8.6M540,126 sh
Point72 Asset Management, L.P.
$8.5M533,965 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$29.1M	1,815,474
VR Adviser, LLC	$26.8M	1,675,262
PERCEPTIVE ADVISORS LLC	$23.2M	1,447,782
Ikarian Capital, LLC	$16.3M	1,017,600
Stonepine Capital Management, LLC	$15.6M	975,200
Logos Global Management LP	$10.0M	625,000
MORGAN STANLEY	$9.5M	596,564
Velan Capital Investment Management LP	$9.3M	583,333
ADAGE CAPITAL PARTNERS GP, L.L.C.	$8.6M	540,126
Point72 Asset Management, L.P.	$8.5M	533,965

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TENX on your watchlist

Track score changes the day TENAX THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TENX a good stock to buy?

13F Pro's AI-powered analysis of TENAX THERAPEUTICS, INC. (TENX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TENX are available on the TENX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TENX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TENX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TENAX THERAPEUTICS, INC.'s investment landscape.